Primary Objectives:~To investigate if the addition of Bevacizumab to standard chemotherapy for metastatic or unresectable GEJ and gastric adenocarcinoma will improve PFS by 90% over historical controls.~Secondary Objectives:~Assess toxicities using CTCAE v3.0~Evaluate overall survival (OS) using Kaplan-Meier analysis~Evaluate objective response rate (RR) by RECIST criteria~Explore biomarkers of tumor response: CEA, CA 19.9, and serum VEGF~Bank serum and tissue for future correlative studies~Evaluate CT Perfusion to predict early therapeutic response to combination chemotherapy and anti-angiogenic therapy (OPTIONAL).
To investigate bevacizumab in combination with carboplatin and capecitabine for patients with unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to standard chemotherapy for this patient population we will improve Progression Free Survival by 90% over historical controls.